DATA GRAPHICS | Data Byte
Upcoming decisions include HER3 ADC from Daiichi-Merck and full approval for Sarepta’s DMD gene therapy
By Gunjan Ohri, Data Content Analyst
June 5, 2024 11:38 PM UTC
FDA is due to make decisions this month on at least six new medicines and nine label expansions. Highlights include the first HER3-targeted antibody-drug conjugate and Sarepta’s DMD gene therapy.
An approval of patritumab deruxtecan from partners Merck & Co. Inc. (NYSE:MRK) and Daiichi Sankyo Co. Ltd. (Tokyo:4568) would make the product first-in-class against HER3…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652620/15-pdufa-dates-on-fda-s-roster-in-june